<DOC>
	<DOCNO>NCT02691494</DOCNO>
	<brief_summary>This study seek evaluate efficacy , safety tolerability elagolix alone combination estradiol/norethindrone acetate management heavy menstrual bleeding associate uterine fibroid premenopausal woman .</brief_summary>
	<brief_title>Efficacy Safety Elagolix Combination With Estradiol/Norethindrone Acetate Management Heavy Menstrual Bleeding Associated With Uterine Fibroids Premenopausal Women ( Replicate Study )</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Menorrhagia</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Subject premenopausal female time Screening . Subject diagnosis uterine fibroid document Pelvic Ultrasound ( TAU , TVU ) . Subject HMB associate uterine fibroid evidence MBL &gt; 80 mL two screening menses measure alkaline hematin method . Subject negative urine and/or serum pregnancy test Screening prior first dose . Subject adequate endometrial biopsy perform Screening , result show clinically significant endometrial pathology . Subject screen pelvic ultrasound SIS result show clinically significant gynecological disorder . Subject history osteoporosis metabolic bone disease . Subject clinically significant abnormality clinical chemistry , hematology , urinalysis . Subject history major depression posttraumatic stress disorder ( PTSD ) within 2 year screen , OR history major psychiatric disorder time ( e.g. , schizophrenia , bipolar disorder ) . Subject use systemic corticosteroid 14 day within 3 month prior Screening likely require treatment systemic corticosteroid course study . Over counter prescription topical , inhale , intranasal injectable ( occasional use ) corticosteroid allow .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>51 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Elagolix</keyword>
	<keyword>Menorrhagia</keyword>
	<keyword>Elagolix + Norethindrone acetate</keyword>
	<keyword>Elagolix Sodium</keyword>
	<keyword>HMB</keyword>
	<keyword>Heavy menstrual bleeding</keyword>
	<keyword>Leiomyomata</keyword>
	<keyword>Heavy uterine bleeding</keyword>
	<keyword>ABT-620</keyword>
	<keyword>Elagolix + E2/NETA</keyword>
</DOC>